Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes of impaired fasting glucose: Results from the LIPID trial

Diabetes Care

Volumn 26, Issue 10, 2003, Pages 2713-2721

  Keech, Anthony ^a   Colquhoun, David ^b   Best, James ^c   Kirby, Adrienne ^a   Simes, R John ^a   Hunt, David ^d   Hague, Wendy ^a   Beller, Elaine ^a   Arulchelvam, Manjula ^a   Baker, Jennifer ^a   Tonkin, Andrew ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESLEY HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; AGED; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; RISK FACTORS; TREATMENT OUTCOME;

EID: 10744228379     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.10.2713     Document Type: Article

References (31)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. CVD Prev 21:1414-1431, 1998
2. National Institute of Diabetes and Digestive and Kidney Diseases: Diabetes Statistics: National Diabetes Information Clearinghouse. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 1999 (NIH publ. no. 99-3926)
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Committee Report). Diabetes Care 20: 1183-1202, 1997
4. American Diabetes Association, National Heart, Lung and Blood Institute, Juvenile Diabetes Foundation International, National Institute of Diabetes and Digestive and Kidney Diseases, American Heart Association: Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation 100:1132-1133, 1999
5. Kannel WB: Lipids, diabetes and coronary heart disease: insights from the Framingham study. Am Heart J 110:1100-1107, 1985
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
7. Barzilay JI, Spiekerman CF, Kuller LH, Burke GL, Bittner V, Gottdiener JS, Brancati FL, Orchard TJ, O'Leary DH, Savage PJ: Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care 24: 1233-1239, 2001
8. Fisman EZ, Motro M, Tenebaum A, Boyko V, Mandelzweig L, Behar S: Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J 141:485-490, 2001
9. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
10. Duckworth WC, McCarren M, Abraira C: Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care 24:942-945, 2001
11. Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP: Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care 14:537-543, 1991
12. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159:2661-2667, 1999
13. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial: the CARE Investigators. Circulation 98:2513-2519, 1998
14. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
15. LIPID Study Group: Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 76:474-479, 1995
16. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
17. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: the West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: the Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335:1001-1009, 1996
20. Lee ET: Statistical Methods for Survival Data Analysis. 2nd ed. New York, Wiley, 1992
21. Cox DR: Regression models and life-tables. J R Stat Soc [B] 34:187-220, 1972
22. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
23. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026-2033, 2001
24. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldins G: Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361: 777-780, 2003
25. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
26. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
27. Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 (Suppl. 5): S1-S85, 1997
28. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003
29. ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007, 2002
30. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH, the Collaborative AtoRvastatin Diabetes Study (CARDS) Investigators: Design of the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 19:201-211, 2002
31. Jonsson B, Cook JR, Pedersen TR: The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 42:1293-1301, 1999